Expertise in
3
conditions

Stefano R. Kim

Besancon, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
3
conditions
Besancon, FR 

Overview

Stefano Kim practices practicing medicine in Besancon, France.

Mr. Kim is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Squamous Cell Carcinoma of the Anal Canal (SCAC), Anal Cancer, Colorectal Cancer, and Agranulocytosis.

He is actively involved in clinical research, co-authoring 83 peer reviewed articles and participating in 12 clinical trials.

Gender

Male

Locations

Besancon, France
Other Locations
Strasbourg, 67200, France
Hospices Civils de Lyon
Lyon, France
Montbeliard, France
Paris, France
Poitiers, France
Dijon, 21000, France
2, Boulevard Tonnellé, Tours, 37000, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: June 24, 2026
Intervention Type: Genetic
LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy
LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2025
Intervention Type: Drug
Study Drug: Trifluridine/Tipiracil
Study Phase: Phase 2
MAZEPPA: Phase II PRODIGE-GERCOR Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients
MAZEPPA: Phase II PRODIGE-GERCOR Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drugs: Olaparib, Durvalumab, Selumetinib, FOLFIRI
Study Phase: Phase 2
Evaluation of Medical Practice in the Management of Bone Metastases After Injectable Bone Antiresorptive Treatment, and Its Influence on Quality of Life
Evaluation of Medical Practice in the Management of Bone Metastases After Injectable Bone Antiresorptive Treatment, and Its Influence on Quality of Life
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Phase: Not Applicable
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
Enrollment Status: Unknown
Publish Date: July 08, 2024
Intervention Type: Drug
Study Drugs: Ramucirumab, Paclitaxel
Study Phase: Phase 2
Multicenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Multicenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Enrollment Status: Unknown
Publish Date: September 28, 2023
Intervention Type: Other
Study Phase: Not Applicable
Prospective Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer
Prospective Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: May 11, 2022
Intervention Type: Other
Study Phase: Not Applicable
Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors
Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors
Enrollment Status: Completed
Publish Date: August 02, 2021
Intervention Type: Drug
Study Drugs: Metronomic cyclophosphamide, Interferon-alpha
Study Phase: Phase 2
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: December 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

83 Total Publications

Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma - Authors' reply.
Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma - Authors' reply.
Journal: The Lancet. Oncology
Published: January 12, 2026

Frequently Asked Questions about Stefano R. Kim

Is Stefano R. Kim a top-rated expert for Squamous Cell Carcinoma of the Anal Canal (SCAC)?

MediFind is an objective health platform that identifies experts based on real-world data. Stefano R. Kim is classified as an Elite expert for Squamous Cell Carcinoma of the Anal Canal (SCAC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Stefano R. Kim participate in research or clinical trials?

Yes. Stefano R. Kim has published 83 articles and abstracts on conditions like Squamous Cell Carcinoma of the Anal Canal (SCAC). You can view a list of Stefano R. Kim's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kim's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile